Lorenson MY, Ueda EK, Chen KE, Walker AM. A major prolactin-binding complex on human milk fat globule membranes contains cyclophilins A and B: the complex is not the prolactin receptor.
Here, we demonstrate that most PRL in human milk is part of a novel, high-affinity, multicomponent binding complex found on the milk fat globule membrane and not in whey. To examine properties of the complex, a sensitive ELISA was developed such that human PRL (hPRL) binding to the complex was measured by loss of hPRL detectability; thus, as much as 50 ng of hPRL was undetectable in the presence of 10 l of human milk. Using the same methodology, no comparable complex formation was observed with human serum or amniotic fluid. hPRL complexation in milk was rapid, time dependent, and cooperative. Antibodies to or competitors of the hPRL receptor (placental lactogen and growth hormone) showed the hPRL receptor was not involved in the complex. However, hPRL complexation was antagonized by cyclosporine A and anti-cyclophilins. The complex was very stable, resisting dissociation in SDS, urea, and dithiothreitol. Western analysis revealed an ϳ75-kDa complex that included hPRL, cyclophilins A and B, and a 16-kDa cyclophilin A. Compared with noncomplexed hPRL, complexed hPRL in whole milk showed similar activation of STAT5 but markedly delayed activation of ERK. Alteration of signaling suggests that complex formation may alter hPRL biological activity. This is the first report of a unique, multicomponent, high-capacity milk fat reservoir of hPRL; all other analyses of milk PRL have utilized defatted milk.
human breast milk; milk signaling through signal transducer and activator of transcription 5 and extracellular signal-regulated kinase; cyclosporine A ALTHOUGH THE IMPORTANCE OF PROLACTIN (PRL) to the production of human milk is undisputed, the importance of PRL in human milk (12, 20) is more difficult to establish. However, in experimental animals, PRL in the milk promotes maturation of the gastrointestinal epithelium (52) and is transferred intact to the neonatal circulation (17) , where it has the capacity to achieve the myriad of functions attributed to this hormone (reviewed in Refs. 3 and 21) . Milk PRL modulates offspring immune responses (18) and affects pituitary development and hypothalamic control of pituitary function (46) . During lactation, PRL of pituitary origin is transcytosed across the mammary epithelium for specific placement in milk (32) . In addition, PRL synthesized by mammary epithelium (8) may also be contributed to milk.
PRL is also present in human breast ductal fluid in the nonlactating, nonpregnant state (39, 40, 54) and is reportedly up to sixfold more concentrated than in serum (40) . Given the permeability of the junctions between epithelial cells to molecules the size of albumin in the nonlactating state (31) , a higher concentration of PRL in ductal fluid could be achieved by either a high-affinity binding moiety in ductal fluid, apical secretion of PRL made by mammary epithelial cells, or both.
At the outset of these studies, we hypothesized that a PRLbinding protein was responsible for allowing concentration of PRL in ductal fluids in the nonlactating state and that the same binding protein might protect PRL from proteolytic degradation in milk. Therefore, we developed a highly sensitive assay for PRL that would allow us to follow competition for PRL between the putative binding protein and the anti-PRL antibody used in the assay. Furthermore, the protocol allowed assay of very small volumes and the use of whole milk rather than defatted material. The binding activity discovered was due to a complex on milk fat globule membranes (MFGMs) and was not present in whey. Milk fat globules are structures formed by budding of cytoplasmic lipid droplets enveloped by the apical mammary epithelial plasma membrane and a small amount of apical cytosol (53) . This location of the PRL binding complex is of great interest since other investigators looking at PRL in milk (2, 5, 12, 20, 30, 33, 37, 55) have all utilized defatted milk. Formation of such a high-affinity binding complex was apparently specific to milk since human PRL (hPRL) binding was much lower in human serum and undetectable in human amniotic fluid.
We found the hPRL binding complex on MFGMs did not involve the PRL receptor (PRLR) but included cyclophilin A (CypA), cyclophilin B (CypB), and a lower-molecular-weight (16 kDa) CypA immunopositive component (CypA16). These important findings demonstrate that hPRL is delivered to the neonate in a complex with cyclophilins. Furthermore, formation of the complex altered hPRL signal transduction, suggesting that the complex may have a somewhat different biology than unbound hPRL.
MATERIALS AND METHODS
Chicken anti-human PRL IgY (chicken anti-hPRL). Antibody to hPRL was produced in Rhode Island red chickens (Robert Sargeant, Ramona, CA), and IgY was isolated from egg yolks obtained after 60 days using a modification of the method of Akita and Nakai (1). All procedures were performed at 4°C. Yolks (80 -100 g) were stirred with acidified water (3.9 ml of 1 N HCl/l) to a final suspension of 10% (wt/vol) and refrigerated overnight. After centrifugation for 60 min at 22,000 g, the supernatant was filtered followed by precipitation with ammonium sulfate [67 ml of 4.1 M (NH 4)2SO4/100 ml]. After stirring for 1 h and centrifugation for 30 min, the precipitate was resuspended in one-half the original yolk weight (in ml of water), dialyzed against water, and suspended in 0.01 M phosphate-138 mM NaCl-2.7 mM KCl, pH 7.4 (PBS), to the original weight (in ml). Precipitated contaminants were removed by centrifugation at 45,000 g, and IgY was stored at Ϫ20°C in 50% (vol/vol, final) UltraPure glycerol (Sigma, St. Louis, MO). Protein concentration was estimated by A 280 in PBS, and purity was monitored by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE; 4:12%, vol/vol). Electrophoresis supplies and equipment were from Bio-Rad (Ramona, CA). Recovery was 900 -1,200 mg of protein; the working stock solution was 5 mg/ml.
ELISA protocol. In Nunc Maxi-Sorp 96-well flat-bottom plates (Thermo Fisher Scientific, Pittsburgh, PA), 100 l of chicken antihPRL (20 g/ml PBS) was added and incubated overnight at 23°C. After removal of unbound IgY, plates were blocked with 200 l of 1% (wt/vol) bovine serum albumin (BSA; electrophoresis grade; Sigma)-PBS and incubated at 37°C. After 4 h, plates were washed three times with 200 l of 0.2% (wt/vol) BSA-PBS and incubated at 23°C with 100 l of hPRL (0.2-50 ng/ml, 2.5 serial dilution) for Ͼ12 h. If milk or other components were added with PRL, the total volume was kept at 100 l. Plates were then washed three times with 200 l of 0.05 M Tris·HCl, pH 7.5, 0.1 M NaCl, and 0.1% (vol/vol) Tween (TBST), and 100 l 1:7,500 rabbit anti-hPRL [IC-5; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)] and Ϫ1:7,500 goat anti-Rb IgG-horseradish peroxidase (HRP; Sigma) (in TBST-0.2% BSA) was added. Incubations were for 4 h, followed by washing with TBST and detection of bound HRP with 100 l of 3,3=,5,5=-tetramethylbenzidine dihydrochloride (TMB)-peroxide. This was prepared using a 1-mg tablet of 3,3=,5,5=-tetramethylbenzidine dihydrochloride (Sigma), 1 ml of 10X stable H 2O2 substrate buffer (Pierce, Thermo Fisher Scientific, Boston, MA), and 9 ml of H2O. Reactions were terminated with 50 l of 1 N H2SO4 and read after 5 min at 450 nm (Finstruments Microplate Reader, Vienna, VA).
Compounds tested in the ELISA included human whole milk [fresh (Bioreclamation), frozen (Lee Biosolutions, St. Louis, MO)], pepstatin and cyclosporine A (Sigma), protease inhibitors (Mini-Complete cocktail; Roche, South San Francisco, CA), human growth hormone (hGH; Sigma) and human placental lactogen (hPL-1; NIDDK), mouse IgG and mouse anti-hPRLR extracellular domain (1A2B1, Invitrogen, Camarillo, CA), and human CypA and CypB (Prospec, Ness-Ziona, Israel). Although other anti-hPRLRs are available, it should be noted that Galsgaard et al. (15) found that the 1A2B1 antibody was the only commercially available one that recognized the hPRLR in immunohistochemistry and immunoprecipitation studies. Results were similar when different preparations of chicken anti-hPRL or different antibodies for detection of hPRL bound to chicken anti-hPRL were used. For instance, in some assays we used monoclonal anti-hPRL directed against the PRL NH2-or COOH-terminal region [nos. 5602 (DBC Laboratories, London, ON, Canada) and 5601 (BiosPacific, Emeryville, CA), respectively] with the corresponding goat anti-mouse IgG-HRP (Santa Cruz Biotechnology). Similarly, results were unaltered when different preparations of unmodified hPRL and when the pseudophosphorylated hPRL (S179D-PRL) (6) were tested. The assay was specific for hPRL. No cross-reactivity was observed if 50 ng of mouse PRL (AFP-6476-C; NIDDK), bovine PRL (AFP-7170-E, NIDDK), hPL, or hGH was assayed.
If nonspecific immunoglobulins were to be removed from milk or milk fat globule membrane fractions, ␥-bind Sepharose (GE Healthcare, Waukesha, WI) and/or A/G agarose (Pierce, Thermo Fisher Scientific) were used, following the instructions of the manufacturer.
For comparison to the hPRL ELISA, a commercially available hGH ELISA (IBL International, Hamburg, Germany) was utilized. This assay was similar in design to the hPRL ELISA we developed, with antibody precoated plates and hGH addition followed by a second anti-hGH antibody and HRP detection.
Western blotting. MFGMs were subjected to SDS-PAGE and Western blotting after acetone precipitation using standard procedures, except that 1% urea was included in the SDS/dithiothreitol (DTT) solubilization buffer to aid in the dissolution of membranes. Samples were electrophoresed, followed by transfer onto nitrocellulose (7V, 1 h; Semi-Dry Transblot SL, Bio-Rad). Following blocking with 3% (wt/vol) BSA-TBST, the nitrocellulose was incubated overnight at 4°C with antibody (1:1,000) against hPRL, hCypA (Abcam, Cambridge, UK), or hCypB (Sigma). After incubation with HRPlabeled second antibodies (True Blot anti-goat and anti-mouse IgG-HRP; eBioscience, San Diego, CA), activity was detected with High-Glo reagent and high-blot CL X-ray film (Denville Scientific, Metuchen, NJ). Reprobing utilized Restore Plus Western Blot Stripping Buffer (Pierce, Thermo Fisher Scientific).
Sample preparation. Recombinant hPRL was prepared as described previously (6) . Whey was prepared by centrifuging 4 ml of whole milk without or with a protease inhibitor cocktail at 100,000 g for 60 min, followed by retrieval of the infranate. MFGMs were prepared by a modification of the method of Wu et al. (53) . Briefly, whole milk (4 ml) was thawed on ice, mixed with 0.4 g of sucrose, and placed in a centrifuge tube. PBS (40 ml) was layered over the sample and centrifuged at 1,500 g for 20 min at 23°C; the lipid layer was collected. This was repeated four times, and the lipid was combined, diluted to 10 ml (PBS), homogenized (20 strokes; Dounce homogenizer), and centrifuged at 100,000 g for 60 min. The pellet was rehomogenized, centrifuged as before, and suspended in 500 l of PBS.
HC11 cell culture. This normal mouse mammary epithelial cell line was grown on 24-mm Transwell (Corning, NY) clear polyester filter inserts in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 1% penicillin-streptomycin, 5 g/ml insulin, and 10 ng/ml epidermal growth factor at 37°C in a 5% CO2-95% air atmosphere. The cultures were kept for 2 days at confluence before the medium was changed to RPMI-1640 medium containing 10% FBS, 1% penicillin-streptomycin, insulin (10 g/ml), dexamethasone (1 M), and PRL (1 g/ml). After the addition of hormones, the cells were cultured for an additional 9-day period, and medium was replaced every 3 days. Only low-passage number cells were used since continued culture results in reduced tight junction formation (4, 22) .
Transepithelial resistance measurements. Transepithelial resistance (TER) was measured on Transwell filter-grown cells to assess proper monolayer formation. Medium was changed to Advanced RPMI-1640 and allowed to cool to room temperature before using the Epithelial Voltohmmeter (World Precision Instruments, Sarasota, FL). TER measurements were taken after electrode sterilization with ethanol. Calculations for ohms/cm 2 were made by subtracting a blank filter and multiplying by the area of the monolayer [TER (⍀cm2) ϭ (total resistance Ϫ blank resistance) (⍀) ϫ area (cm 2 )] (4.5 cm 2 for the 24-mm filter inserts). Only cultures with Ն400 ohms/cm 2 were used.
Signal generation after engagement of the receptor. To detect activation of signaling molecules, cells were incubated in Advanced RPMI-1640 containing dexamethasone and insulin (as described above) but without PRL for 2 h. They were then treated for the times stated with hPRL (1 g/ml), undiluted human milk, or undiluted human milk treated with anti-hPRL. Cells were extracted in ice-cold lysate buffer [0.14 M NaCl, 20 mM Tris base, 10 mM Na 2P2O7, 10 mM NaF, 1 mM Na 3VO4, 1% (vol/vol) NP-40, 0.02% (wt/vol) NaN3, and 0.5 mM EDTA] supplemented with protease inhibitor cocktail, followed by 2 freeze-and-thaw cycles. Lysate proteins were resolved by SDS-PAGE and subsequently transferred to a polyvinylidene fluoride membrane. To assess ERK activation, after blocking with 5% skim milk proteins, the membrane was incubated with anti-phospho-ERK (recognizing tyrosine phosphorylation, 1:1,000; Santa Cruz Biotechnology). The blots were stripped and reprobed with anti-total ERK (1:1,000; Santa Cruz Biotechnology). Antigen-antibody interactions were detected using HRP-coupled secondary antibodies (1:2,000 for 1 h) and enhanced chemiluminescence (Amersham Biosciences, Piscataway, NJ).
For STAT5 activation, cell lysates were precleared by incubation with protein A-Sepharose beads at 4°C for 1 h. The sample was then incubated with the beads precoupled with anti-STAT5A/B antibody or a rabbit nonspecific ␥-globulin (Santa Cruz Biotechnology) for 18 h at 4°C. After washing, bound components were eluted by boiling in gel sample buffer for 5 min. Blots were probed with antibodies against phosphotyrosine, stripped, and reprobed with anti-total STAT5 (1:1,000; Santa Cruz Biotechnology).
Statistical analyses. All results are presented as the mean A 450 Ϯ SE after subtraction of the reagent blank, unless noted otherwise. The number of experiments utilized for each determination is given in the figure legends. Statistical analyses were carried out using t-tests for paired comparisons or an IBM SPSS-17 program in which multiple comparisons were carried out with one-way ANOVA and Dunnet T3 or Games-Howell. Data were considered significantly different if P values were Ͻ0.05 (t-test with correction for multiple comparisons).
RESULTS

Human milk inhibition of PRL detection by ELISA.
A sensitive ELISA for hPRL was developed in which the hormone first binds to chicken anti-hPRL precoated on a 96-well plate. Bound hPRL is then detected using rabbit anti-hPRL and goat anti-rabbit IgG-HRP. Thus, sites for both the chicken antibody and the second anti-hPRL are accessible on hPRL. The working range was between 0.05 and 2 ng. The assay was specific for hPRL since no absorbance above background was observed when 50 ng of mouse PRL or 50 ng of bovine PRL was assayed. Since PRL in human milk was reportedly between 14 and 40 ng/ml (12, 20) , PRL in 10 l of milk (0.1-0.4 ng) should have been detectable in the assay. However, no immunoassayable PRL was observable in whole human milk (Fig. 1A) . Also, if human milk was added to hPRL, it markedly inhibited detection of the standard (Fig. 1 , B and C). In . 1D ). The milk binding capacity was large since PRLbinding saturation of 0.5 l of milk was not achieved until close to 400 ng (160 nM) (Fig. 1D) . Similarly, as much as 50 ng hPRL was not measureable in this very sensitive assay in the presence of 10 l of milk (not shown).
Loss of detectability in the assay was not due to milk opacity since after milk addition the plate was washed six times (200 l each), and virtually all milk was removed prior to color development. Furthermore, opacity would have resulted in higher and not lower absorbances. The inhibition of hPRL assayability by milk was not related to a general effect of milk on ELISAs because the dramatic, cooperative inhibition was not observed when whole human milk was included in a hGH ELISA (data not shown). Additionally, inhibition was not observed when bovine whole milk was utilized in place of human milk in the hPRL ELISA (data not shown). Furthermore, results were not artifacts incurred by freezing human milk, because the results were unchanged when fresh human milk was used (data not shown). Therefore, frozen human milk was utilized in all studies described below.
The time needed for milk to inhibit hPRL assayability was tested. Plates were coated with anti-hPRL and blocked, and hPRL was added. Milk was included in the incubation for 20 h or it replaced the buffer for the final 5-min, 30-min, or 2-h portion of the 20-h incubation. After incubation, plates were washed three times and incubated with detection antibodies, as described in MATERIALS AND METHODS. Results in Fig. 2 are expressed as a percent of hPRL (with milk/without milk) incubated for identical times. Results show that the interaction between milk and hPRL occurred even when the PRL had already been bound to antibody. Moreover, it was rapid, with differences being observed at 5 min. To be assured that the milk had no direct effect on the antibody, anti-hPRL-coated plates were treated with or without milk in the absence of hPRL. Then, plates were washed, and hPRL was added and incubated as described above. No effect of milk pretreatment was observed, confirming that inhibition was not due to a direct interaction between anti-hPRL and milk (not shown). was incubated with 0.5 l of whole milk for 16 h at room temperature. After samples were diluted to be within the ELISA range (0.1-2.5 ng), duplicate 100-l aliquots were added to plates precoated with chicken anti-hPRL and blocked with BSA. A Hill coefficient of ϩ2.5 was calculated using Prism GraphPad software.
The effect of adding human milk to the ELISA was compared with the effect of adding human serum to the immunoassay. As seen in Fig. 3 , milk () was markedly more potent in reducing the detection of 2 ng of hPRL than was human female serum ( ' ). With 1 l of serum, for example, the assayability of hPRL was not significantly reduced compared with ϳ80% inhibition with 1 l of milk. Approximately 30% inhibition was reached with 10 l of serum that compared with complete inhibition of hPRL assayability with 10 l of milk. The small effect of serum compared with milk was not due to nonspecific serum components, since female rat serum () had no effect on the assayability of the hPRL. Human amniotic fluid (2nd trimester) was also tested. The measured hPRL concentration was high (Ͼ500 ng/ml), and, upon addition of 2 ng of hPRL to 1, 2, or 5 l of amniotic fluid, no discernible binding activity was detected (data not shown).
Human milk inhibition of PRL detectability is not due to proteases or the PRLR. Several experiments ruled out proteases as being responsible for milk inhibition of assayability (data not shown). First, if all buffers and milk included a protease inhibitor cocktail or pepstatin A (5 M), no change was observed. Second, results were similar whether the detecting antibody was a polyclonal anti-hPRL or one specific for either the hPRL NH 2 -or COOH-terminal region. Finally, preincubation of hPRL with milk at 4, 23, or 37°C prior to addition to the ELISA made no difference. One would have expected temperature differences if degradation was involved. However, the factor necessary for inhibition is heat sensitive (data not shown); milk heated to 65°C (for 30 min) required three times the amount for 50% inhibition of 1 ng of hPRL (1.5 l of heated vs. 0.45 l of unheated milk). Heating milk for Յ3 h at 65°C resulted in some detection of released hPRL, but this could not be used to detect the amount of bound hPRL because the hPRL itself was not stable at this temperature (i.e., heat decreased PRL standard curves with time at 65°C; data not shown).
A soluble form of the PRLR has been described in human milk (1, 24, 30) . We utilized three approaches to determine whether a PRLR was responsible for milk inhibition of hPRL assayability. First, we asked whether inhibition could be removed by preclearing milk with an anti-hPRLR antibody. After removal of nonspecific immunoglobulins with ␥-Bind G Sepharose beads, milk (100 l) was incubated for 16 h at 4°C with 0.5 g of anti-hPRLR extracellular domain. It should be noted that although there have been controversies in the literature regarding the validity and sensitivity of some antibodies against hPRLR, the antibody used (1A2B1) is reportedly the best commercially available antibody for accurately recognizing hPRLR (15) . Antibodies were removed by incubation for 5.5 h at 4°C with 10 l of A/G agarose. After treatment, inhibition of hPRL assayability by milk was unchanged (Fig. 4A) .
Our second approach utilized known competition between hPRL and human placental lactogen (hPL) for the hPRLR (3). If hPRLR in milk was responsible for binding hPRL, hPL would be expected to compete for the binding sites and increase detectability of hPRL. As seen in Fig. 4B , it is clear that there was no effect of 12.8 (X) or 80 ng hPL () on inhibition of assayability of 2 ng of hPRL by 0.1-10 l milk. Controls indicated that there was no cross-reactivity in the ELISA between hPRL and hPL (2-200 ng hPL; ࡗ) and no effect of hPL on the assayability of 2 ng of hPRL in the absence of milk ( ' ). Since zinc may be necessary for hPL binding to the hPRLR (27, 50) , experiments were duplicated in the presence of 50 M zinc. Again, no differences were observed (data not shown).
hGH binds to the hPRLR (3), and in the presence of 50 M zinc, affinity is increased 8,000-fold (10), resulting in hGH binding up to six times stronger than hPRL. Thus, if the PRLR was involved in the observed milk inhibition of hPRL detection, hGH in the presence of zinc would be expected to block inhibition. In our third approach, zinc (50 M) was included without or with 50 ng of hGH in combination with hPRL (0.5, 1, or 2 ng) and whole milk (0, 0.6, 1.6, or 4 l). Results shown in Fig. 4C clearly demonstrates that the PRLR is not involved since, regardless of the concentration of hPRL, hGH had no effect on hPRL assayability whether alone or coincubated with human milk. experiments for milk and averages of 2 experiments for the sera. The presence of human serum was different from hPRL alone (P Ͻ 0.004), but rat serum was not (P Ͼ 0.05).
Human milk inhibition of PRL detectability is due to a PRL binding complex on MFGMs.
We asked how others detected PRL in human milk, whereas none was detectable with this ELISA. The difference most likely was that others used whey or skimmed milk. Milk obtained in the 1st week following delivery has the highest PRL concentration (12, 20) . As shown in Fig. 5A , no PRL was detected in whole human milk collected in the 1st week. However, hPRL was measurable in whey isolated from this milk (0.18 ng of hPRL/10 l or 18 ng of hPRL/ml). PRL was also detectable in whey obtained after 2 wk of lactation, but values approached the assay's lower limit (not shown). When we questioned whether whey inhibited hPRL assayability, we found dramatic differences between whey and milk (Fig. 5B) . Whereas whole human milk markedly inhibited detection of standard hPRL, whey had no effect. Similar data were obtained irrespective of collection times after childbirth (not shown). Since the soluble hPRLR described by others is present in whey (2, 24, 30) and whey had no effect, this is further evidence that inhibition of assayability with whole milk in the ELISA was due to a binding factor(s) independent of a soluble PRLR.
Convinced that milk inhibition of hPRL detection was not due to protease digestion or to a soluble PRLR and that the binding factor was in whole milk and not in whey, we turned our attention to components of milk fat and questioned whether a binding factor on the MFGM was involved. As seen in Fig. 6 , MFGMs inhibited hPRL assayability when incubated with 2 or 0.13 ng PRL. MFGMs (ϳ1 g protein) resulted in an ϳ50% loss of hPRL detection.
The PRL binding complex involves cyclophilins. Since forms of CypA and CypB have been identified in human milk (14, 28) and MFGMs (14) , and since CypB binds PRL (43), we questioned whether PRL might associate with a member of the cyclophilin family. To test this, we utilized cyclosporin A (CsA), which binds and inhibits cyclophilins (23) . Milk inhibition of assayability was counteracted by CsA (Fig. 7) , and the response to CsA was dose related, with essentially complete reversal of inhibition with 3 g of CsA. CsA itself had no effect on the standard curve (not shown).
We then tested whether anti-cyclophilins could influence human milk or MFGM inhibition of hPRL assayability. ELISA plates were pretreated with anti-hPRL and blocked with BSA, followed by the addition of milk or MFGMs with buffer, anti-CypA, anti-CypB, or both anti-CypA and anti-CypB (1/ 250 each). After 4 h, hPRL was added, plates were incubated overnight at room temperature, and the amount of detectable hPRL was determined. It should be noted that the anti-cyclophilins were specific since, on Western blot analysis, antiCypA did not detect CypB and anti-CypB did not detect CypA. Using either MFGMs or milk, it was clear that both CypA and CypB were involved in the hPRL binding complex. For example, MFGMs (5 l) inhibited hPRL (0.8 ng) detection 95%; with MFGMs and anti-CypA, inhibition was only 20% (P Ͻ 0.005), and with MFGMs and anti-CypB, inhibition was 50% (P Ͻ 0.005). In a similar experiment, milk (0.8 l) inhibited hPRL (2 ng) detection 89%, whereas with milk and anti-CypA, 60% inhibition was observed (P Ͻ 0.001). With milk and both anti-CypA and anti-CypB present, only 37% inhibition (P Ͻ 0.002) was seen. Clearly, both CypA and CypB were integral to hPRL binding.
Partial characterization of the interactions among MFGMs, hPRL, and cyclophilins was achieved by analysis of Western blots. MFGMs were incubated overnight at pH 7.5 without or with added hPRL or 5 mM zinc. Zinc was tested since it is known to bind and inhibit isomerase activity (25) . Following incubation, samples were pelleted, washed with PBS, treated with acetone to remove buffer ions and some lipids, and treated with PAGE sample buffer containing 1 M urea. In the Western blots, we used True-Blot HRP second antibodies to probe for anti-hPRL, anti-CypA, or anti-CypB so that IgG heavy and light chains would not complicate interpretations. Again, antibodies against CypA did not detect CypB standards and vice versa. With membrane samples, a positive band was observed for all probes close to 75 kDa (Fig. 8A) . The complex was not an artifact due to heating of the MFGMs, since the results were unchanged if samples were incubated in SDS-DTT-urea for 24 h at room temperature (data not shown). The ϳ75-kDa band was not present in the absence of MFGMs because no 75-kDa band was observed in the lanes containing hPRL or Cyp standards . No hPRL, CypB, or CypA was detected as monomers (23, 21 , and 18 kDa, respectively), and thus, no dissolution of complex occurred during the SDS-DTT-urea treatment of membranes. Addition of hPRL to MFGM incubations resulted in stronger positive 75-kDa bands, suggesting that the hPRL binding sites were not previously saturated. The addition of zinc also resulted in stronger bands at 75 kDa, suggesting that zinc has a stabilizing effect on the complex. Fig. 8 . Analysis of the MFGM complex. A: presence of immunopositive bands for hPRL, human cyclophilin A (CypA), and human cyclophilin B (CypB) at ϳ75 kDa on Western blots of MFGMs. Membranes were incubated overnight at 23°C without or with hPRL. Replicate lanes on an 11/4% gel included standards (S), membranes (M), membranes plus hPRL (ϩP), and membranes plus 5 mM zinc (ϩZ). Wells contained 50 g of MFGM proteins with or without 60 ng of hPRL. Detection was with anti-hCypA, anti-hCypB, or anti-hPRL. Shown are the 75-kDa region and the monomeric region; no positive bands were noted at the monomeric sizes except in standard positive controls (S). B: presence of CypA and CypB in MFGM supernates. MFGMs (50 g) were incubated overnight at 23°C without or with 5 mM zinc without or with 8 ng of hPRL. Western blotting of acetone-precipitated supernatants after electrophoresis (10 -20% gradient) was with a mix of anti-hCypA and anti-hCypB (1:1,000 each). C: identification of CypA16. Western blots of membrane supernates (Sup) and standard (Std) CypB or CypA were probed with anti-hCypB or anti-hCypA. All gels (A-C) were representative of 3 or more experiments. D: lack of milk inhibition of hPRL assayability with zinc. PRL (2 ng) was incubated for 16 h on anti-hPRL precoated plates, followed by a 3-h incubation with milk (0.1-10 l) without () or with 5 mM ZnCl2 ( ' ).
Results are presented as the %hPRL without milk. E: influence of Nonidet P-40 on milk inhibition of assayability of 2 ng of hPRL. Milk (0.05-5 l) without (ࡗ) or with 0.1% Nonidet P-40 () was incubated with 2 ng of hPRL in the ELISA for 16 h. The hPRL detected is expressed as the %hPRL in the absence of milk. No interference in the hPRL standard curve was observed with 0.1% Nonidet P-40 (not shown). Results in D and E are averages of duplicate determinations; a minimum of 3 experiments were carried out under similar conditions. Fig. 7 . Effect of cyclosporine A (CsA) on milk inhibition of hPRL assayability. PRL (0.13-5 ng) was incubated in the absence (ࡗ) of whole milk or with 0.5 l of milk and either 0 (), 1.2 (), or 3.1 g of CsA ( ' ). CsA alone (added to the assay in ethanol) had no effect on the standard curve (not shown). Note that data are presented as in Fig. 1C (plotted vs hPRL) . Results presented are averages of duplicate determinations. Other experiments under similar conditions gave comparable results.
Western blots of supernatants from overnight incubations of MFGMs incubated alone, with or without hPRL, and with or without zinc are shown in Fig. 8B . Without zinc or hPRL, some CypA and CypB was released from membranes and, therefore, was found in the supernatant. Interestingly, a smaller-molecular-weight CypA positive band (ϳ16 kDa; CypA16) was the major Cyp observed in the supernate (identity established in Fig. 8C ). In contrast, no CypA16 was released into the supernate when membranes were incubated with zinc, although other Cyps were still visible. Dramatic increases in the release of all Cyps was observed with membrane exposure to hPRL, suggesting that there was some equilibrium between the bound and free constituents of the complex. However, incubations with PRL and zinc resulted in a reduction in CypA and CypB and, again, no detectable CypA16 released from the membranes into the supernate.
With the combined effects of zinc on increasing the amount of the ϳ75-kDa complex and decreasing the amount of CypA16 released from MFGMs, we tested its ability to affect milk inhibition of hPRL assayability in the ELISA. No milk inhibition was observed when Յ10 l of milk was incubated for 3 h with 2 ng of hPRL and 5 mM zinc (Fig. 8D ). In addition, incubating membranes with zinc (0.5 or 5 mM) did not result in significant amounts of PRL detected by ELISA (data not shown). Thus, zinc affects the hPRL-Cyp interaction by stabilizing the complex on the membrane, by not allowing release of detectable amounts of PRL, and by preventing complexation of additional PRL.
Coincubation of standard CypA, CypB, and hPRL without membranes was not sufficient for complex formation under conditions as in Fig. 8A experiments (data not shown) . No complexes were observed on electrophoresis unless MFGMs were present. Moreover, the ability to electrophoretically separate complex components from supernatants of MFGM incubations (Fig. 8B) suggested that treatment of membranes with nonionic detergents might reduce hPRL/Cyp affinities for one another. Membranes were incubated in 0.1% Nonidet P-40, and their ability to inhibit assayability was examined. This concentration of Nonidet P-40 did not affect the hPRL standard curve. Incubation of membranes in this nonionic detergent decreased inhibition of assayability close to threefold (Fig. 8E) . Incubation of membranes with Յ1% Nonidet P-40 did not result in detection of PRL in the ELISA (data not shown), thus suggesting that, like zinc, the nonionic detergent prevented PRL binding and did not result in dissolution of the complex.
Signaling of milk. We questioned the functional consequences of having hPRL tightly complexed in milk. This was tested using normal mouse mammary epithelial cells (HC11) grown as polarized monolayers to mimic breast duct architecture. Activation of signaling pathways was monitored after cells were apically exposed to standard hPRL (1 g/ml), whole milk, or milk treated with anti-hPRL. As shown in Fig. 9 , in the presence of hPRL, phospho-ERK was detected after 10 min, and some signal remained until 60 min. In contrast, in the presence of milk, no phospho (p)-ERK signal was observed unless cells were incubated for 3 h. Regarding STAT5 activation, little difference between milk and standard hPRL was observed, with only a slight delay of phospho-STAT5 detection from 5 (with hPRL) to 15 min (with milk). If cells were incubated with anti-PRL-treated milk, p-ERK and p-STAT 5 were diminished, indicating that these signals were the result of hPRL in milk and not some other factor (data not shown). Clearly, although hPRL is tightly bound in milk, it is still functionally relevant for signal transduction, but the effect is modified from that of noncomplexed hPRL.
DISCUSSION
Human milk rapidly inhibited the assayability of standard hPRL. The effect was very rapid, being detectable within 5 min of incubation, suggesting that a high-affinity binding protein in milk rapidly sequestered PRL. This was supported by a determination that milk inhibited assayability even if hPRL was first prebound to anti-hPRL on the plates without milk. Thus, the binding affinity of the milk component was much greater than the PRL-antibody interaction, placing the binding protein affinity well above the normal range for antigen-IgY interactions of 10 8   -10 12 M (26). Others have described a hPRL-binding protein in the whey fraction of human milk (2, 24, 30) that they identified as the extracellular domain of the hPRLR (24) . A similar finding was described in rabbit defatted milk (37) . In the present studies, the hPRL-binding factor is not present in whey and not related to the hPRLR. Furthermore, since the whey fraction had no effect on assayability in our hands, any soluble hPRLR present in whey must be low in concentration or of lower affinity than the antibody used in this ELISA. The hPRL-binding complex we describe in milk is associated with the MFGM. This localization is extremely significant since studies reporting differences in milk PRL levels under different physiological conditions have used only whey (e.g., see Refs. 5, 33, and 55). By assaying only the soluble portion of milk, PRL concentrations may be severely underestimated. Fig. 9 . Signaling of milk hPRL compared with standard hPRL. Polarized monolayers of HCll cells were incubated without PRL for 2 h prior to treatment for the indicated time periods with hPRL (1 g/ml; A and B) or undiluted whole human milk (C and D). Phosphorylated ERK (p-ERK; A and C) was detected after cell lysis, SDS-PAGE, and Western blotting (WB) using anti-phospho-ERK; total ERK was determined after stripping and reprobing with anti-ERK. STAT5 activation (B and D) was determined after cell lysis, immunoprecipitation (IP) with anti-STAT5A/B-coupled Sepharose beads, SDS-PAGE, WB, and probing with anti-phosphotyrosine. Total STAT5 was assessed after stripping and reprobing with anti-STAT5. Results given are representative of 3 experiments.
Loss of hPRL detection was also observed in human serum, although the effect was much less potent than in milk (i.e., 1 l of serum had negligible effects, whereas 1 l of milk reduced detection by 80%). It is not known whether the low effect in serum was due to the soluble PRLR-related binding protein described previously (2, 24, 30) , but this seems likely at present. In amniotic fluid, hPRL levels were high, and there was no evidence of a similar binding complex.
Analysis of the human MFGM proteome (14) , along with work in the literature showing interplay among Cyps, hPRL, and the hPRLR (42, 43, 56) , suggested that Cyps could be involved in the observed hPRL binding in milk. Proteomic studies have identified CypA in human colostral MFGMs (14) , and CypB is found in nipple aspirate fluid (34) and is detected as a truncated form in skim milk (28) . Furthermore, Western blot analysis in the present studies showed that both CypA and CypB were present in human MFGMs. CypB is a secreted protein with a classical signal sequence (38) . Therefore, its presence on MFGM would require it to be bound to an integral membrane protein. CypA is classically considered a cytosolic protein, but analyses of membrane-enclosed viral particles have shown that it can be transmembrane and that a small proportion of the CypA molecule can be extracellularly available to bind to other moieties (44) . Forms of CypA can also be secreted (36, 48) , and this may account for the more readily dissociable 16-kDa CypA-positive material. A reduction in human milk inhibition of hPRL assayability with CsA was consistent with the possibility that CsA blocked an interaction between cyclophilins on the MFGM and hPRL. Because zinc inhibits Cyp activity (25) , loss of inhibition of assayability in the presence of 5 mM zinc was also compatible with a role for cyclophilins. Antibodies against CypA and CypB each diminished milk or MFGM inhibition of assayability, and reduction in inhibition was even greater when both antibodies were present.
On Western blots of MFGM proteins, we identified a band close to 75 kDa that was positive for hPRL, CypA, and CypB, suggesting a complex of these proteins. Binding was so strong that the complex survived 100°C for 5 min in SDS-DTT-1 M urea, consistent with the very high-affinity interaction observed in the ELISA. MFGMs were not saturated in terms of hPRL binding capacity since additional hPRL increased the hPRLpositive ϳ75-kDa band. This was not unexpected, because in the ELISA even 50 ng of hPRL was undetectable when incubated with 10 l of milk.
When MFGMs were incubated overnight, CypA16 was identified in the supernate along with CypA and CypB. A low-molecular-weight CypA has been described in human decidual and placental tissue (29) , but it is as yet unclear whether this is the same entity. Zinc prevented the release of CypA16, a finding that correlates with loss of milk inhibition of assayability. The molecular weight of the complex in the membrane is compatible with a 1:1:1:1 complex among CypA, CypB, CypA16, and hPRL without additional membrane components. Membranes appear necessary for the formation of the complex inasmuch as disruption of membranes with Nonidet P-40 resulted in a loss of inhibition of assayability. However, once formed, the complex was very stable, resisting dissociation with SDS-DTT-1 M urea. The multicomponent nature of the complex is also consistent with the observed steepness of the inhibition curve in the assay, which is itself indicative of a cooperative interaction. We suggest a working model consistent with the data in which hPRL associates with CypA, CypB, and/or CypA16 on the MFGM. The high-affinity complex is then formed rapidly after cyclophilin prolyl peptidyl-cis/trans isomerase action alters the conformation of at least one of the components. These isomerases are able to modulate multiple substrates, including hPRL (11, 19, 43, 51) . A possible isomerase site on hPRL is P94, a highly conserved proline that best fits the criteria for a Cyp-active site (11, 19, 43, 51) . Isomerization here would affect hPRL conformation by distortion of helix 2. Since zinc has such a dramatic influence on CypA16, this moiety may be inhibited directly by the divalent cation, resulting in a loss of ability to dissociate from the membrane.
Not only may the binding complex in milk carry hPRL to the neonate, but the large reservoir of bound hPRL may be more protected from potential proteolytic degradation. Additionally, the binding complex may affect functionality at target receptors. In the signaling studies, it appears that the high-affinity complex in milk of hPRL and Cyps resulted in a form of PRL that was still recognized by the receptor; it caused STAT5 signal transduction but markedly delayed ERK activation. It has been shown previously for related cytokine receptors that altered receptor orientation in the dimer affects differential activation of the Jak2/STAT5 and ERK pathways (41, 45) . Therefore, it seems likely that the way in which the complex and free hPRL interact with the receptor causes a slightly different receptor orientation. Given the affinity of the various components of the complex for one another in milk, it does not seem likely that the Cyps would dissociate outside the target cell. However, they may dissociate once they have interacted with the receptor and through this interaction been placed inside an endocytic vesicle. In this regard, different roles for Cyps in hPRL signaling have been described previously; CypA is required for Jak2 activation after engagement of the PRLR (56) , and CypB is a cofactor for some STAT5-mediated gene expression (42) .
Since in previous work defatted milk has been used to measure hPRL, the amount of hPRL in whole milk may be significantly greater than assumed previously. This suggests an important role in the neonate consistent with the demonstrated roles of hPRL in gastrointestinal maturation and neuroendocrine and immune development in animal studies (18, 46, 52) . With regard to immune development, the Cyps in the complex on MFGMs may play a role in their own right since they are also immunomodulatory (51) .
In addition to its role in the neonate, there may be a function for the hPRL-binding complex in the luminal compartment of the mammary gland. Ductal fluids in the nonpregnant and nonlactating state contain concentrated hPRL (39, 40, 54) , both CypA and CypB (34) , and epithelial membrane fragments (34) . Additionally, PRLR expression is found on the luminal side of mammary epithelium in male gynecomastia (13) , and in animal studies the distribution of PRLRs is primarily on the luminal side, except in midlactation (49) . Therefore, it is possible that the binding complex we have described in milk also functions in the nonpregnant, nonlactating state, serving to not only sequester PRL but also, as shown in the HC11 experiments, alter PRL-PRLR interactions. A large number of in vitro and some epidemiological studies support a role for PRL in breast cancer promotion (reviewed in Ref. 8 ). However, in early-stage breast cancer, activated STAT5 in the nucleus is indicative of a better prognosis (35) . The vast majority of breast cancer arises from ductal epithelium (8) where PRLRs have been localized to the apical surface (7, 13, 16, 44) . Thus, the presence of a PRL-binding complex in the duct lumen could be a crucial local modulator of PRL function. How this fits with the clinical observation that the cyclophilin isomerase inhibitor CsA is protective against breast cancer (47) is presently not resolved. Cyclophilins play a role in so many cellular processes and immune-mediated events. On the one hand, since CsA reduces complex formation, more PRL would be available for cell stimulation. But on the other hand, CsA may inhibit Cyp A-mediated activation of Jak2 (56), thereby negating the effect of liberated PRL.
Studies that enhance our knowledge of the cooperative interactions between PRL and this newly recognized binding complex may provide new insights into the role of PRL in milk and its benefit to the neonate. Furthermore, our understanding of the dynamic equilibrium between bound and free PRL in ductal fluids of the breast may enhance our understanding of normal mammary function and potentially treatment of breast cancer.
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